XENOPAT
Contact information
- Drug development
- Oncology
- CRO / CMO / SMO
At Xenopat, we specialise in preclinical oncology services, providing innovative in vivo models to accelerate the development of new cancer therapies. We conduct in vivo toxicity and efficacy studies to support the development of safer and more effective treatments. Our advanced models and technologies inform decision-making across the entire drug development pipeline, from preclinical research to clinical trials and post-commercialisation. Using a range of platforms, including cell-derived xenografts (CDX), syngeneic models, patient-derived xenografts (PDX) and humanised mouse models, we tailor our solutions to maximise success in oncology drug development.
Xenopat – Preclinical Oncology Services
At Xenopat, we specialise in preclinical oncology services, providing innovative in vivo models to accelerate the development of new cancer therapies.
1.Toxicology Studies
We conduct comprehensive in vivo toxicology studies to support safe and effective drug development, including:
• Route of administration optimisation
• Determination of Maximum Tolerated Dose (MTD)
• Dosing schedule definition
• Pharmacokinetics (PK)
• Biodistribution studies
2.Drug Efficacy Studies
- Basic Preclinical Models
• Cell-Derived Xenograft (CDX) models
• Syngeneic models
- Advanced Preclinical Models
• Patient-Derived Xenograft (PDX) models (more than 450 PDX)
• Humanised mouse models for immunotherapy evaluation
• Metastatic models
• Non-neoplastic models
3.Co-Clinical Trials and Translational Services
• Generation of PDX models from clinical trial samples
• Drug repurposing studies to identify new therapeutic indications
4.Histology and Pathology Services
• Haematoxylin and Eosin (H&E) staining
• Immunohistochemistry (IHC)
• Histopathological analysis performed by an in-house medical pathologist
5.Consulting and Strategic Support
• Design of preclinical and co-clinical studies
• Drafting and review of in vivo sections for research proposals and funded projects
6.Personalised Cancer Treatment Assessment
• Guidance of patient treatment strategies based on scientific evidence
• Execution of co-clinical trials to develop tailored therapeutic approaches
Xenopat is interested in establishing strategic collaborations and alliances with biotechnology, pharmaceutical, diagnostic and academic partners across the oncology innovation ecosystem. We seek partnerships with pharma and biotech companies requiring robust in vivo efficacy testing in high-quality preclinical models, as well as synergies with companies performing in vitro analyses that require an in vivo partner, and clinical research organisations interested in developing co-clinical trials using our technologies. We are also open to participating in public–private partnerships and funded national and European collaborative projects.